



ASX/MEDIA RELEASE

18th May 2017

Personnel Change

Sydney, Australia; 18th May 2017 – Sirtex Medical Limited (ASX:SRX) today announces Mr Kevin Richardson, CEO of the Americas has ceased employment with the Company, effective immediately.

Mr Nigel Lange, Interim CEO of Sirtex Medical said “On behalf of Sirtex, I would like to thank Mr Richardson for his commitment to the business over the last seven years.”

Mr Lange continued “I am pleased to announce the appointment of Mr Tom Payne to the position of Acting Vice President of Sales, effective immediately. Mr Payne brings a wealth of experience to the organisation with over 30 years of senior executive experience within the medical device industry and is a welcome addition to our Americas sales team.”

Sirtex will be conducting a thorough executive search process to identify a suitable internal or external candidate to fill the position left by Mr Richardson.

About Sirtex Medical

Sirtex Medical Limited (ASX:SRX) is an Australian-based global healthcare business working to improve outcomes in people with cancer. Our current lead product is a targeted radiation therapy for liver cancer. Over 73,000 doses have been supplied to treat patients with liver cancer at 1,060 medical centres in over 40 countries. For more information please visit www.sirtex.com.

For further information, please contact:

Investor Enquiries:

Mr Nigel Lange
Interim CEO
Sirtex Medical Limited
Phone: +61 (0) 2 9964 8400

Investor/Media Enquiries:

Dr Tom Duthy
Global Investor Relations Manager
Sirtex Medical Limited
Phone: +61 (0) 2 9964 8427
Email: tduthy@sirtex.com

Head Office
Level 33, 101 Miller Street
North Sydney, NSW 2060
Australia

Americas
300 Unicorn Park Drive
Woburn, MA 01801
United States

Europe, Middle East & Africa
Josef-Schumpeter-Allee 33
53227 Bonn
Germany

Asia Pacific
50 Science Park Road, #01-01
The Kendall Science Park II
Singapore 117406